Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors (...)
Semaglutide, the active ingredient in Novo's Wegovy and Ozempic, and tirzepatide, sold as Zepbound and Mounjaro by Lilly, are so effective that they should be the first choice in almost all cases when substantial weight loss is necessary, according to a new guideline from the European (...)
Site référencé: The Economic Times
The Economic Times
Raymond Lifestyle shares slide 4% as Income Tax Department conducts survey at offices and units
26/09/2025
CarTrade shares more than double in 1 year. Elara sees 36% upside, here's why
26/09/2025
Defence stocks offer long-term visibility, but valuations still stretched : Sandip Sabharwal
26/09/2025
HAL shares up 15% in 2025, analysts see potential rally up to Rs 6,220. Here’s why
26/09/2025
Bitcoin falls over 2% to $109K, signaling short-term caution in crypto market
26/09/2025
GK Energy shares rally 7% after D-Street debut, IPO investors see 15% gains
26/09/2025
